share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K：重大事件
美股SEC公告 ·  11/05 05:12

Moomoo AI 已提取核心信息

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the third quarter ended September 29, 2024, on November 4, 2024. The company announced a slight decrease in Core Illumina revenue to $1.1 billion for Q3 2024, a 2% drop from Q3 2023. Despite the revenue decline, Illumina experienced a significant increase in GAAP operating margin to 68.6% and a non-GAAP operating margin of 22.6% for the same period. The GAAP diluted EPS was $4.03, and non-GAAP diluted EPS was $1.14 for Q3 2024. Illumina also adjusted its fiscal year 2024 guidance, expecting a revenue decline of approximately 3% from the previous year but raised its non-GAAP operating margin guidance to a range of 21% to 21.5% and non-GAAP diluted EPS guidance to $4.05 to $4.15. The company's financial outlook was revised due to the constrained macroeconomic environment, although the demand for Illumina's products remains strong. The company's press release also highlighted the spin-off of GRAIL on June 24, 2024, and several strategic initiatives and product launches aimed at accelerating revenue growth and margin expansion.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the third quarter ended September 29, 2024, on November 4, 2024. The company announced a slight decrease in Core Illumina revenue to $1.1 billion for Q3 2024, a 2% drop from Q3 2023. Despite the revenue decline, Illumina experienced a significant increase in GAAP operating margin to 68.6% and a non-GAAP operating margin of 22.6% for the same period. The GAAP diluted EPS was $4.03, and non-GAAP diluted EPS was $1.14 for Q3 2024. Illumina also adjusted its fiscal year 2024 guidance, expecting a revenue decline of approximately 3% from the previous year but raised its non-GAAP operating margin guidance to a range of 21% to 21.5% and non-GAAP diluted EPS guidance to $4.05 to $4.15. The company's financial outlook was revised due to the constrained macroeconomic environment, although the demand for Illumina's products remains strong. The company's press release also highlighted the spin-off of GRAIL on June 24, 2024, and several strategic initiatives and product launches aimed at accelerating revenue growth and margin expansion.
全球领先的DNA测序和基于阵列技术的illumina公司报告了截至2024年9月29日第三季度的财务业绩，时间为2024年11月4日。该公司宣布，核心illumina营业收入略有下降，为11亿美元，较2023年第三季度下降2%。尽管营业收入下降，illumina在同一期间的美国通用会计原则（GAAP）营业利润率大幅增加至68.6%，非美国通用会计原则（非GAAP）营业利润率为22.6%。第三季度2024年的GAAP摊薄后每股收益为4.03美元，非GAAP摊薄后每股收益为1.14美元。illumina还调整了其2024财年的指引，预计与上一年相比收入将下降约3%，但将非GAAP营业利润率指引提高...展开全部
全球领先的DNA测序和基于阵列技术的illumina公司报告了截至2024年9月29日第三季度的财务业绩，时间为2024年11月4日。该公司宣布，核心illumina营业收入略有下降，为11亿美元，较2023年第三季度下降2%。尽管营业收入下降，illumina在同一期间的美国通用会计原则（GAAP）营业利润率大幅增加至68.6%，非美国通用会计原则（非GAAP）营业利润率为22.6%。第三季度2024年的GAAP摊薄后每股收益为4.03美元，非GAAP摊薄后每股收益为1.14美元。illumina还调整了其2024财年的指引，预计与上一年相比收入将下降约3%，但将非GAAP营业利润率指引提高至21%至21.5%，非GAAP摊薄后每股收益指引为4.05至4.15美元。由于宏观经济环境的限制，公司的财务前景已调整，尽管illumina产品的需求仍然强劲。该公司的新闻发布还强调了于2024年6月24日分拆GRAIL以及几项旨在加速营收增长和利润率扩张的战略举措和产品推出。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间